Base de dados : MEDLINE
Pesquisa : D03.383.725.676.925.875 [Categoria DeCS]
Referências encontradas : 6284 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 629 ir para página                         

  1 / 6284 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
[PMID]:29378102
[Au] Autor:Pilipenko VI; Teplyuk DA; Shakhovskaya AK; Isakov VA; Vorobyova VM; Vorobyova IS; Glazkova IV; Kochetkova AA; Mikheeva GA; Yudina AV
[Ti] Título:[Dry jelly concentrate with vitamins and dietary fiber in patients with IBS with constipation: a comparative controlled study].
[So] Source:Vopr Pitan;84(6):83-91, 2015.
[Is] ISSN:0042-8833
[Cp] País de publicação:Russia (Federation)
[La] Idioma:rus
[Ab] Resumo:Irritable bowel syndrome (IBS) is highly prevalent functional gastrointestinal disorder associated with decrease in quality of life and a high social cost. Diet is one of several therapeutic options in IBS treatment; therefore the development and clinical evaluation of innovative functional food for IBS patients is useful. Dry jelly concentrate containing 3 g inulin, 10 mg curcumin and 1.8 mg of pyridoxine was developed and clinically evaluated. Fifty patients fulfilling the Rome III criteria for IBS-C were randomly assigned into two groups: one received standard diet plus two jelly drinks a day for 2 weeks and control group received standard diet. Response to therapy was recorded on a daily basis using Likert scale of abdominal pain, bloating and feeling of incomplete bowel emptying, frequency of bowel movement, Bristol stool scale, and quality of life assessed by IBSQoL questionnaire before and after the treatment. Intake of functional food product (jelly) containing inulin and curcumin is associated with a significant positive effect on the stool parameters (from 0.6±0.24 to 1.15±0.65 t/d in stool frequency, p=0.001, from 2.62±1.23 to 3.99±1.27, index Bristol scale, p=0.001), a reduce of the severity of abdominal pain (from 1.69±0.71 to 1.36±0.44 Likert scale points, p=0.001), bloating (from 2.03±0.89 to 1.55±0.81 points of Likert scale, p=0.02) and a sense of incomplete bowel emptying (from 2.25±0.98 to 1.68±0.92 points of Likert scale, p=0.001), as well as an increase in quality of life (from 64.5±13.5 to 81.2±9.1%, Ñ€=0.05). Patients in control group have improvement in abdominal pain (from 2.16±0.58 to 1.8±0.61 Likert scale points, p=0.05) and bloating (from 2.42±0.83 to 2.16±0.71 Likert scale points, p=0.05) only. During the treatment period no significant adverse events were found. These results indicate that jelly concentrate containing inulin, curcumin and pyridoxine improves abdominal pain score, Bristol scale index and quality of life in patients with IBS-C.
[Mh] Termos MeSH primário: Bebidas
Constipação Intestinal
Fibras na Dieta/administração & dosagem
Síndrome do Intestino Irritável
Vitaminas/administração & dosagem
[Mh] Termos MeSH secundário: Adulto
Idoso
Constipação Intestinal/dietoterapia
Constipação Intestinal/fisiopatologia
Curcumina/administração & dosagem
Feminino
Seres Humanos
Inulina/administração & dosagem
Síndrome do Intestino Irritável/dietoterapia
Síndrome do Intestino Irritável/fisiopatologia
Masculino
Meia-Idade
Piridoxina/administração & dosagem
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Dietary Fiber); 0 (Vitamins); 9005-80-5 (Inulin); IT942ZTH98 (Curcumin); KV2JZ1BI6Z (Pyridoxine)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180216
[Lr] Data última revisão:
180216
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180130
[St] Status:MEDLINE


  2 / 6284 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Registro de Ensaios Clínicos
Texto completo
[PMID]:29342163
[Au] Autor:Persaud N; Meaney C; El-Emam K; Moineddin R; Thorpe K
[Ad] Endereço:Department of Family and Community Medicine and Li Ka Shing Knowledge Institute, St Michael's Hospital, Toronto, Ontario, Canada.
[Ti] Título:Doxylamine-pyridoxine for nausea and vomiting of pregnancy randomized placebo controlled trial: Prespecified analyses and reanalysis.
[So] Source:PLoS One;13(1):e0189978, 2018.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Doxylamine-pyridoxine is recommended as a first line treatment for nausea and vomiting during pregnancy and it is commonly prescribed. We re-analysed the findings of a previously reported superiority trial of doxylamine-pyridoxine for the treatment of nausea and vomiting during pregnancy using the clinical study report obtained from Health Canada. METHODS AND FINDINGS: We re-analysed individual level data for a parallel arm randomized controlled trial that was conducted in six outpatient obstetrical practices in the United States. Pregnant women between 7 and 14 weeks of gestation with moderate nausea and vomiting of pregnancy symptoms. The active treatment was a tablet containing both doxylamine 10 mg and pyridoxine 10 mg taken between 2 and 4 times per day for 14 days depending on symptoms. The control was an identical placebo tablet taken using the same instructions. The primary outcome measure was improvement in nausea and vomiting of symptoms scores using the 13-point pregnancy unique quantification of emesis scale between baseline and 14 days using an ANCOVA. 140 participants were randomized into each group. Data for 131 active treatment participants and 125 control participants were analysed. On the final day of the trial, 101 active treatment participants and 86 control participants provided primary outcome measures. There was greater improvement in symptoms scores with doxylamine-pyridoxine compared with placebo (0.73 points; 95% CI 0.21 to 1.25) when last observation carried forward imputation was used for missing data but the difference is not statistically significant using other approaches to missing data (e.g. 0.38; 95% CI -0.08 to 0.84 using complete data). CONCLUSIONS: There is a trend towards efficacy for nausea and vomiting symptoms with doxylamine-pyridoxine compared with placebo but the statistical significance of the difference depends on the method of handling missing data and the magnitude of the difference suggests that there is no clinically important benefit employing the prespecified minimal clinically important difference or "expected difference" of 3 points. TRIAL REGISTRATION: Clinical Trial NCT00614445.
[Mh] Termos MeSH primário: Doxilamina/administração & dosagem
Êmese Gravídica/prevenção & controle
Piridoxina/administração & dosagem
[Mh] Termos MeSH secundário: Quimioterapia Combinada
Feminino
Seres Humanos
Placebos
Gravidez
[Pt] Tipo de publicação:JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Placebos); 95QB77JKPL (Doxylamine); KV2JZ1BI6Z (Pyridoxine)
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180207
[Lr] Data última revisão:
180207
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180118
[Cl] Clinical Trial:ClinicalTrial
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0189978


  3 / 6284 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29227608
[Au] Autor:Golovenko NY; Larionov VB; Karpova OV
[Ti] Título:Physical-chemical properties and the reactivity of pyridoxine and pyrrolidone carboxylate and their protolytic forms.
[So] Source:Ukr Biochem J;88(2):73-81, 2016 Mar-Apr.
[Is] ISSN:2409-4943
[Cp] País de publicação:Ukraine
[La] Idioma:eng
[Ab] Resumo:Preparation Methadoxine is equimolar salt, which cationic component (pyridoxine) is 3-oxypyridine derivative, possessing B6-vitamine like activity, while anionic component is the cyclic lactame of glutamic acid. Since biopharmaceutical and pharmacological properties of this drug depend on biochemical transformation its components, of the aim of this work was to determine the structure of possible ionized pyridoxine and pyrrolidone carboxylate forms and their reaction ability in biochemical processes. Physical-chemical properties of compounds (pKa, logP, logD, proton donor/acceptor quantity, solubility (g/l)) were calculated with ACD/pKaDB program or obtained from Pub-Med physical/chemical properties database. UV spectra of compounds were obtained after dissolution in different pH solutions (1.0, 4.5 and 6.8). It was found that at different pH values one can observe changes of the absorption spectra due to the presence of prevailing amount of the protonated form. An analysis of both pKa, logP and logD indicators and reactive functional groups of Methadoxine components has revealed that they can be protonated in different regions of gastro-intestinal tract, that influences their solubility in hydrophilic and lypophilic media. Pharmacological properties of pyridoxine and pyrrolidone carboxylate themselves are performed after their preliminary biotransformation to active metabolites. Only ionic interaction between Methadoxine components in the substance composition can appear, that provides its pharmaceutical stability and ensures its activity only in the organism conditions.
[Mh] Termos MeSH primário: Ácido Glutâmico/química
Lactamas Macrocíclicas/química
Prótons
Piridoxina/química
Ácido Pirrolidonocarboxílico/química
[Mh] Termos MeSH secundário: Estabilidade de Medicamentos
Concentração de Íons de Hidrogênio
Interações Hidrofóbicas e Hidrofílicas
Solubilidade
Soluções
Espectrofotometria Ultravioleta
Água/química
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Lactams, Macrocyclic); 0 (Protons); 0 (Solutions); 059QF0KO0R (Water); 3KX376GY7L (Glutamic Acid); KV2JZ1BI6Z (Pyridoxine); SZB83O1W42 (Pyrrolidonecarboxylic Acid)
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180116
[Lr] Data última revisão:
180116
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171212
[St] Status:MEDLINE
[do] DOI:10.15407/ubj88.02.073


  4 / 6284 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27778219
[Au] Autor:Morris AA; Kozich V; Santra S; Andria G; Ben-Omran TI; Chakrapani AB; Crushell E; Henderson MJ; Hochuli M; Huemer M; Janssen MC; Maillot F; Mayne PD; McNulty J; Morrison TM; Ogier H; O'Sullivan S; Pavlíková M; de Almeida IT; Terry A; Yap S; Blom HJ; Chapman KA
[Ad] Endereço:Institute of Human Development, University of Manchester, Manchester, UK. Andrew.morris@cmft.nhs.uk.
[Ti] Título:Guidelines for the diagnosis and management of cystathionine beta-synthase deficiency.
[So] Source:J Inherit Metab Dis;40(1):49-74, 2017 Jan.
[Is] ISSN:1573-2665
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:Cystathionine beta-synthase (CBS) deficiency is a rare inherited disorder in the methionine catabolic pathway, in which the impaired synthesis of cystathionine leads to accumulation of homocysteine. Patients can present to many different specialists and diagnosis is often delayed. Severely affected patients usually present in childhood with ectopia lentis, learning difficulties and skeletal abnormalities. These patients generally require treatment with a low-methionine diet and/or betaine. In contrast, mildly affected patients are likely to present as adults with thromboembolism and to respond to treatment with pyridoxine. In this article, we present recommendations for the diagnosis and management of CBS deficiency, based on a systematic review of the literature. Unfortunately, the quality of the evidence is poor, as it often is for rare diseases. We strongly recommend measuring the plasma total homocysteine concentrations in any patient whose clinical features suggest the diagnosis. Our recommendations may help to standardise testing for pyridoxine responsiveness. Current evidence suggests that patients are unlikely to develop complications if the plasma total homocysteine concentration is maintained below 120 µmol/L. Nevertheless, we recommend keeping the concentration below 100 µmol/L because levels fluctuate and the complications associated with high levels are so serious.
[Mh] Termos MeSH primário: Cistationina beta-Sintase/deficiência
Homocistinúria/dietoterapia
Homocistinúria/tratamento farmacológico
[Mh] Termos MeSH secundário: Betaína/metabolismo
Homocisteína/metabolismo
Seres Humanos
Metionina/metabolismo
Piridoxina/uso terapêutico
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0LVT1QZ0BA (Homocysteine); 3SCV180C9W (Betaine); AE28F7PNPL (Methionine); EC 4.2.1.22 (Cystathionine beta-Synthase); KV2JZ1BI6Z (Pyridoxine)
[Em] Mês de entrada:1712
[Cu] Atualização por classe:171204
[Lr] Data última revisão:
171204
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161026
[St] Status:MEDLINE
[do] DOI:10.1007/s10545-016-9979-0


  5 / 6284 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29053735
[Au] Autor:Zabinyakov N; Bullivant G; Cao F; Fernandez Ojeda M; Jia ZP; Wen XY; Dowling JJ; Salomons GS; Mercimek-Andrews S
[Ad] Endereço:Genetics and Genome Biology Program, Research Institute, The Hospital for Sick Children, Toronto, Canada.
[Ti] Título:Characterization of the first knock-out aldh7a1 zebrafish model for pyridoxine-dependent epilepsy using CRISPR-Cas9 technology.
[So] Source:PLoS One;12(10):e0186645, 2017.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Pyridoxine dependent epilepsy (PDE) is caused by likely pathogenic variants in ALDH7A1 (PDE-ALDH7A1) and inherited autosomal recessively. Neurotoxic alpha-amino adipic semialdehyde (alpha-AASA), piperideine 6-carboxylate and pipecolic acid accumulate in body fluids. Neonatal or infantile onset seizures refractory to anti-epileptic medications are clinical features. Treatment with pyridoxine, arginine and lysine-restricted diet does not normalize neurodevelopmental outcome or accumulation of neurotoxic metabolites. There is no animal model for high throughput drug screening. For this reason, we developed and characterized the first knock-out aldh7a1 zebrafish model using CRISPR-Cas9 technology. Zebrafish aldh7a1 mutants were generated by using a vector free method of CRISPR-Cas9 mutagenesis. Genotype analysis of aldh7a1 knock-out zebrafish was performed by high resolution melt analysis, direct sequencing and QIAxcel system. Electroencephalogram was performed. Alpha-AASA, piperideine 6-carboxylate and pipecolic acid, were measured by liquid chromatography-tandem mass spectrometry. Our knock-out aldh7a1 zebrafish has homozygous 5 base pair (bp) mutation in ALDH7A1. Knock-out aldh7a1 embryos have spontaneous rapid increase in locomotion and a rapid circling swim behavior earliest 8-day post fertilization (dpf). Electroencephalogram revealed large amplitude spike discharges compared to wild type. Knock-out aldh7a1 embryos have elevated alpha-AASA, piperideine 6-carboxylate and pipecolic acid compared to wild type embryos at 3 dpf. Knock-out aldh7a1 embryos showed no aldh7a1 protein by western blot compared to wild type. Our knock-out aldh7a1 zebrafish is a well characterized model for large-scale drug screening using behavioral and biochemical features and accurately recapitulates the human PDE-ALDH7A1 disease.
[Mh] Termos MeSH primário: Aldeído Desidrogenase/genética
Repetições Palindrômicas Curtas Agrupadas e Regularmente Espaçadas
Epilepsia/induzido quimicamente
Piridoxina/toxicidade
Peixe-Zebra/genética
[Mh] Termos MeSH secundário: Potenciais de Ação
Animais
Comportamento Animal
Eletroencefalografia
Epilepsia/genética
Epilepsia/fisiopatologia
Técnicas de Silenciamento de Genes
Peixe-Zebra/embriologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
EC 1.2.1.3 (Aldehyde Dehydrogenase); KV2JZ1BI6Z (Pyridoxine)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171113
[Lr] Data última revisão:
171113
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171021
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0186645


  6 / 6284 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28763984
[Au] Autor:Banipal PK; Sharma M; Banipal TS
[Ad] Endereço:Department of Chemistry, Guru Nanak Dev University, Amritsar 143005, India. Electronic address: pkbanipal@yahoo.com.
[Ti] Título:Solvation behavior and sweetness response of carbohydrates, their derivatives and sugar alcohols in thiamine HCl (vitamin B1) and pyridoxine HCl (vitamin B6) at different temperatures.
[So] Source:Food Chem;237:181-190, 2017 Dec 15.
[Is] ISSN:0308-8146
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Volumetric properties are important tools to study the solvation behavior of solutes and reveal valuable information about solute-solute/cosolute interactions. Therefore, standard partial molar volumes at infinite dilution have been calculated from density measurements for monosaccharides, their methoxy and deoxy derivatives, disaccharides and sugar alcohols in (0.05, 0.15, 0.25 and 0.35)molkg thiamine HCl and pyridoxine HCl solutions over temperature range (288.15-318.15)K at pressure, p=0.1MPa. The corresponding transfer volumes, expansibilities and apparent massic volumes have been evaluated to examine the solvation behavior and the basic taste quality of studied solutes. UV-Vis absorption study of these solutes has also been carried out in 1.0×10 molkg thiamine HCl and pyridoxine HCl solutions. Results have been compared with our previously reported studies carried out in l-ascorbic acid (vitamin C). Stereochemical effects on hydration controlled by dominant conformations of studied solutes have also been discussed.
[Mh] Termos MeSH primário: Carboidratos/química
[Mh] Termos MeSH secundário: Piridoxina
Solubilidade
Álcoois Açúcares
Temperatura Ambiente
Tiamina
Vitamina B 6
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Carbohydrates); 0 (Sugar Alcohols); 8059-24-3 (Vitamin B 6); KV2JZ1BI6Z (Pyridoxine); X66NSO3N35 (Thiamine)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171101
[Lr] Data última revisão:
171101
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170803
[St] Status:MEDLINE


  7 / 6284 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28723333
[Au] Autor:Hakim J; Musiime V; Szubert AJ; Mallewa J; Siika A; Agutu C; Walker S; Pett SL; Bwakura-Dangarembizi M; Lugemwa A; Kaunda S; Karoney M; Musoro G; Kabahenda S; Nathoo K; Maitland K; Griffiths A; Thomason MJ; Kityo C; Mugyenyi P; Prendergast AJ; Walker AS; Gibb DM; REALITY Trial Team
[Ad] Endereço:From the University of Zimbabwe Clinical Research Center, Harare, Zimbabwe (J.H., M.B.-D., G.M., K.N.); Joint Clinical Research Center, Kampala (V.M., C.K., P.M.), Mbarara (A.L.), and Fort Portal (S. Kabahenda) - all in Uganda; Medical Research Council Clinical Trials Unit at University College Lond
[Ti] Título:Enhanced Prophylaxis plus Antiretroviral Therapy for Advanced HIV Infection in Africa.
[So] Source:N Engl J Med;377(3):233-245, 2017 07 20.
[Is] ISSN:1533-4406
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: In sub-Saharan Africa, among patients with advanced human immunodeficiency virus (HIV) infection, the rate of death from infection (including tuberculosis and cryptococcus) shortly after the initiation of antiretroviral therapy (ART) is approximately 10%. METHODS: In this factorial open-label trial conducted in Uganda, Zimbabwe, Malawi, and Kenya, we enrolled HIV-infected adults and children 5 years of age or older who had not received previous ART and were starting ART with a CD4+ count of fewer than 100 cells per cubic millimeter. They underwent simultaneous randomization to receive enhanced antimicrobial prophylaxis or standard prophylaxis, adjunctive raltegravir or no raltegravir, and supplementary food or no supplementary food. Here, we report on the effects of enhanced antimicrobial prophylaxis, which consisted of continuous trimethoprim-sulfamethoxazole plus at least 12 weeks of isoniazid-pyridoxine (coformulated with trimethoprim-sulfamethoxazole in a single fixed-dose combination tablet), 12 weeks of fluconazole, 5 days of azithromycin, and a single dose of albendazole, as compared with standard prophylaxis (trimethoprim-sulfamethoxazole alone). The primary end point was 24-week mortality. RESULTS: A total of 1805 patients (1733 adults and 72 children or adolescents) underwent randomization to receive either enhanced prophylaxis (906 patients) or standard prophylaxis (899 patients) and were followed for 48 weeks (loss to follow-up, 3.1%). The median baseline CD4+ count was 37 cells per cubic millimeter, but 854 patients (47.3%) were asymptomatic or mildly symptomatic. In the Kaplan-Meier analysis at 24 weeks, the rate of death with enhanced prophylaxis was lower than that with standard prophylaxis (80 patients [8.9% vs. 108 [12.2%]; hazard ratio, 0.73; 95% confidence interval [CI], 0.55 to 0.98; P=0.03); 98 patients (11.0%) and 127 (14.4%), respectively, had died by 48 weeks (hazard ratio, 0.76; 95% CI, 0.58 to 0.99; P=0.04). Patients in the enhanced-prophylaxis group had significantly lower rates of tuberculosis (P=0.02), cryptococcal infection (P=0.01), oral or esophageal candidiasis (P=0.02), death of unknown cause (P=0.03), and new hospitalization (P=0.03). However, there was no significant between-group difference in the rate of severe bacterial infection (P=0.32). There were nonsignificantly lower rates of serious adverse events and grade 4 adverse events in the enhanced-prophylaxis group (P=0.08 and P=0.09, respectively). Rates of HIV viral suppression and adherence to ART were similar in the two groups. CONCLUSIONS: Among HIV-infected patients with advanced immunosuppression, enhanced antimicrobial prophylaxis combined with ART resulted in reduced rates of death at both 24 weeks and 48 weeks without compromising viral suppression or increasing toxic effects. (Funded by the Medical Research Council and others; REALITY Current Controlled Trials number, ISRCTN43622374 .).
[Mh] Termos MeSH primário: Infecções Oportunistas Relacionadas com a AIDS/prevenção & controle
Anti-Infecciosos/uso terapêutico
Antirretrovirais/uso terapêutico
Infecções por HIV/tratamento farmacológico
[Mh] Termos MeSH secundário: Adolescente
Adulto
África ao Sul do Saara/epidemiologia
Idoso
Anti-Infecciosos/efeitos adversos
Antirretrovirais/efeitos adversos
Contagem de Linfócito CD4
Criança
Quimioterapia Combinada
Feminino
Infecções por HIV/mortalidade
Seres Humanos
Isoniazida/uso terapêutico
Estimativa de Kaplan-Meier
Masculino
Meia-Idade
Piridoxina/uso terapêutico
Combinação Trimetoprima e Sulfametoxazol/uso terapêutico
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Anti-Infective Agents); 0 (Anti-Retroviral Agents); 8064-90-2 (Trimethoprim, Sulfamethoxazole Drug Combination); KV2JZ1BI6Z (Pyridoxine); V83O1VOZ8L (Isoniazid)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170922
[Lr] Data última revisão:
170922
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170721
[St] Status:MEDLINE
[do] DOI:10.1056/NEJMoa1615822


  8 / 6284 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28644307
[Au] Autor:Susanto TAK; Bhattacharyya R
[Ad] Endereço:*Department of Paediatric †Department of Paediatrics Haematology/Oncology Service, KK Women's and Children's Hospital, Singapore.
[Ti] Título:X-linked Sideroblastic Anemia in a Malay Boy With ALAS2 S568G Mutation.
[So] Source:J Pediatr Hematol Oncol;39(5):408-409, 2017 Jul.
[Is] ISSN:1536-3678
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Dimorphism in peripheral blood film was noted in a 16 year old Malay boy with anemia who was eventually diagnosed with X-linked sideroblastic anemia. A mutation in ALAS2 S568G was identified which has not been described previously in a Malay ethnic group.
[Mh] Termos MeSH primário: 5-Aminolevulinato Sintetase/genética
Anemia Sideroblástica/diagnóstico
Doenças Genéticas Ligadas ao Cromossomo X/diagnóstico
Mutação
[Mh] Termos MeSH secundário: Adolescente
Anemia Sideroblástica/tratamento farmacológico
Anemia Sideroblástica/etnologia
Anemia Sideroblástica/genética
Doenças Genéticas Ligadas ao Cromossomo X/tratamento farmacológico
Doenças Genéticas Ligadas ao Cromossomo X/etnologia
Doenças Genéticas Ligadas ao Cromossomo X/genética
Hemoglobinas/análise
Seres Humanos
Malásia
Masculino
Piridoxina/uso terapêutico
Caracteres Sexuais
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Hemoglobins); EC 2.3.1.37 (5-Aminolevulinate Synthetase); EC 2.3.1.37 (ALAS2 protein, human); KV2JZ1BI6Z (Pyridoxine)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170922
[Lr] Data última revisão:
170922
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170624
[St] Status:MEDLINE
[do] DOI:10.1097/MPH.0000000000000814


  9 / 6284 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:28511162
[Au] Autor:Babinets LS; Kytsai KY; Kotsaba YY; Halabitska IM; Melnyk NA; Semenova IV; Zemlyak OS
[Ad] Endereço:Department Of Primary Health Care And General Practice/Family Medicine. Shei "Ternopil State Medical University By I. Horbachevsky Of Mph Of Ukraine", Ternopil, Ukraine.
[Ti] Título:Improvement of the complex medical treatment for the patients wÑ–th chronic biliary pancreatitis.
[So] Source:Wiad Lek;70(2):213-216, 2017.
[Is] ISSN:0043-5147
[Cp] País de publicação:Poland
[La] Idioma:eng
[Ab] Resumo:INTRODUCTION: The most common reason of chronic pancreatitis is liver and bile ducts disease: functional disorders, chronic cholecystitis, cholelithiasis and cholecystectomy in medical history. All these changes are associated with the colloidal structure of bile, increased lithogenicity, gallstones formation, Oddi's sphincter dysfunction, dysmotility and inflammation in the bile ducts. THE AIM: to study the effectiveness of using medicine Liveria IC (metadoxine) in standard therapy as well as effect on spectrum of blood serum lipids and structural condition of liver (stiffness) and pancreas in patients with chronic biliary pancreatitis combined with obesity. MATERIALS AND METHOD: 115 patients suffering from chronic biliary pancreatitis and obesity were the subjects of the study. They were compared to etiological factor socioeconomic conditions and nutrition (regular food 5 times a day without aggressive food (fatty, spicy, sour, fried products)). Also the effect of the alcohol factor was excluded. RESULTS: The obtained decrease in stiffness of the liver and pancreas indicates an improvement of their structural state. CONCLUSIONS: Using medication LiveriaIC (metadoxine) as the part of the complex therapy for the patients who are suffering from CBP combined with obesity gives some improvement of the lipid profile indices and the structural condition of liver and pancreas (according to the data of SWE) (Ñ€<0.05).
[Mh] Termos MeSH primário: Fígado/efeitos dos fármacos
Pâncreas/efeitos dos fármacos
Pancreatite Crônica/tratamento farmacológico
Piridoxina/uso terapêutico
Ácido Pirrolidonocarboxílico/uso terapêutico
[Mh] Termos MeSH secundário: Colecistectomia/efeitos adversos
Colecistite/complicações
Colelitíase/complicações
Combinação de Medicamentos
Feminino
Seres Humanos
Fígado/patologia
Masculino
Meia-Idade
Obesidade/complicações
Pâncreas/patologia
Pancreatite Crônica/etiologia
Pancreatite Crônica/patologia
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Drug Combinations); EJQ7M98H5J (metadoxine); KV2JZ1BI6Z (Pyridoxine); SZB83O1W42 (Pyrrolidonecarboxylic Acid)
[Em] Mês de entrada:1707
[Cu] Atualização por classe:170707
[Lr] Data última revisão:
170707
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170517
[St] Status:MEDLINE


  10 / 6284 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28267984
[Au] Autor:Yang X; Qiang X; Li Y; Luo L; Xu R; Zheng Y; Cao Z; Tan Z; Deng Y
[Ad] Endereço:Department of Medicinal Chemistry, Key Laboratory of Drug Targeting and Drug Delivery System of the Education Ministry, West China School of Pharmacy, Sichuan University, Chengdu 610041, China.
[Ti] Título:Pyridoxine-resveratrol hybrids Mannich base derivatives as novel dual inhibitors of AChE and MAO-B with antioxidant and metal-chelating properties for the treatment of Alzheimer's disease.
[So] Source:Bioorg Chem;71:305-314, 2017 Apr.
[Is] ISSN:1090-2120
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:A series of pyridoxine-resveratrol hybrids Mannich base derivatives as multifunctional agents have been designed, synthesized and evaluated for cholinesterase (ChE) and monoamine oxidase (MAO) inhibitory activity. To further explore the multifunctional properties of the new derivatives, their antioxidant activities and metal-chelating properties were also tested. The results showed that most of these compounds could selectively inhibit acetylcholinesterase (AChE) and MAO-B. Among them, compounds 7d and 8b exhibited the highest potency for AChE inhibition with IC values of 2.11µM and 1.56µM, respectively, and compound 7e exhibited the highest MAO-B inhibition with an IC value of 2.68µM. The inhibition kinetic analysis revealed that compound 7d showed a mixed-type inhibition, binding simultaneously to the CAS and PAS of AChE. Molecular modeling study was also performed to investigate the binding mode of these hybrids with MAO-B. In addition, all target compounds displayed good antioxidant and metal-chelating properties. Taken together, these preliminary findings can be a new starting point for further development of multifunctional agents for Alzheimer's disease.
[Mh] Termos MeSH primário: Antioxidantes/farmacologia
Quelantes/farmacologia
Inibidores da Colinesterase/farmacologia
Inibidores da Monoaminoxidase/farmacologia
Monoaminoxidase/metabolismo
Piridoxina/farmacologia
Estilbenos/farmacologia
[Mh] Termos MeSH secundário: Acetilcolinesterase/metabolismo
Doença de Alzheimer/tratamento farmacológico
Doença de Alzheimer/enzimologia
Animais
Antioxidantes/química
Quelantes/química
Inibidores da Colinesterase/química
Electrophorus
Seres Humanos
Cinética
Bases de Mannich/química
Bases de Mannich/farmacologia
Metais/metabolismo
Modelos Moleculares
Inibidores da Monoaminoxidase/química
Piridoxina/análogos & derivados
Ratos
Estilbenos/química
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antioxidants); 0 (Chelating Agents); 0 (Cholinesterase Inhibitors); 0 (Mannich Bases); 0 (Metals); 0 (Monoamine Oxidase Inhibitors); 0 (Stilbenes); EC 1.4.3.4 (Monoamine Oxidase); EC 3.1.1.7 (Acetylcholinesterase); KV2JZ1BI6Z (Pyridoxine); Q369O8926L (resveratrol)
[Em] Mês de entrada:1706
[Cu] Atualização por classe:170606
[Lr] Data última revisão:
170606
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170308
[St] Status:MEDLINE



página 1 de 629 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde